hyperprolactinemia
HYPERPROLACTINEMIA
Hyperprolactinemia is the presence of elevated prolactin levels that occurs in about one-thirds of patients w/ chronic kidney disease & resolves after successful transplantation.
It may cause visual field defects or headache in both men and women.
In women, signs and symptoms include menstrual irregularity, galactorrhea, infertility, vaginal dryness, dyspareunia, loss of libido and reduction in vertebral bone density (in sustained, pronounced hyperprolactinemia).
While in men, signs and symptoms include diminished libido, hypogonadism, gonadotrophin suppression, osteopenia, decreased muscle mass, and decreased facial hair that may occur in prolonged hyperprolactinemia.

Surgical Intervention

Transsphenoidal Surgery

  • Preferred method
    • Craniotomy is rarely performed

Indications:

  • Patients who are resistant to or exhibit non-tolerance to optimal medical therapy
  • Patients w/ intrasellar tumor & long-term medical treatment is not acceptable
  • Patients w/ tumors pressing on the optic chiasm
  • Effects:
    • Microprolactinomas: Initially 70% achieve prolactin (PRL) normalization
    • Macroprolactinomas: Only 30% are successfully resected
    • Recurrence of microprolactinomas & macroprolactinomas occurs in 20% of patients w/in 1 year of surgery
    • Recurrence rates reach 50% in long-term follow-up of macroprolactinomas
  • Potential complications: Usually infrequent when performed by experienced surgeons
    • Mortality rate: 0.3%
    • Morbidity rate: 0.4%
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 20 Jul 2018
Women with pre-eclampsia or gestational hypertension during their first pregnancy had an increased risk of developing chronic hypertension, type 2 diabetes (T2D), and hypercholesterolaemia than those who were normotensive during pregnancy, according to a study. The risk persisted for several decades later, signalling these hypertensive disorders of pregnancy (HDP) as red flags for cardiovascular (CV) health for life.
Roshini Claire Anthony, 30 Jul 2018

Canagliflozin may provide a renoprotective effect in individuals with type 2 diabetes (T2D) and a history of cardiovascular disease (CVD), according to results from the CANVAS* Program.

Stephen Padilla, 31 Jul 2018
Patients with type 2 diabetes (T2D) treated with sulphonylureas as second-line drugs are at an increased risk of myocardial infarction (MI), all-cause mortality and severe hypoglycaemia compared with those who remained on metformin monotherapy, a recent study has found.
22 Jul 2018
There appears to be a nonlinear relationship between total oestradiol and free oestradiol and all-cause mortality among older men, according to data from the Three-City cohort study. Specifically, the association is stronger for cardiovascular disease mortality and nonexistent for cancer mortality.